ADAR1 Capital Management, LLC bought $9.5M of KROS
owner at Keros Therapeutics, Inc.. 934,258 shares at an average of $10.13, traded Apr 9, 2025, filed Apr 11, 2025.
Score components
- +12Role10% owner
- +25Trade size$9.5M at market
- +6Relative to holdingsHoldings up 27%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-034321, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 9, 2025 | POpen-market purchase Common Stockindirect: By ADAR1 Partners, LP | +18,560 | $9.40 | $174k | 3,493,404 | Apr 11, 2025 |
| Apr 9, 2025 | POpen-market purchase Common Stockindirect: By Spearhead Insurance Solutions IDF, LLC | +16,365 | $9.40 | $154k | 743,558 | Apr 11, 2025 |
| Apr 9, 2025 | POpen-market purchase Common Stockindirect: By ADAR1 Partners, LP | +325,000 | $9.86 | $3.2M | 3,818,404 | Apr 11, 2025 |
| Apr 9, 2025 | POpen-market purchase Common Stockindirect: By ADAR1 Partners, LP | +500,000 | $10.33 | $5.2M | 4,318,404 | Apr 11, 2025 |
| Apr 9, 2025 | POpen-market purchase Common Stockindirect: By ADAR1 Partners, LP | +74,333 | $10.33 | $768k | 4,392,737 | Apr 11, 2025 |
| Apr 9, 2025 | JOther Cash-Settled Total Return Swapsderivativeindirect: By ADAR1 Partners, LP | -325,000 | - | - | 624,333 | Apr 11, 2025 |
| Apr 9, 2025 | JOther Cash-Settled Total Return Swapsderivativeindirect: By ADAR1 Partners, LP | -500,000 | - | - | 124,333 | Apr 11, 2025 |
| Apr 9, 2025 | JOther Cash Settled Total Return Swapsderivativeindirect: By ADAR1 Partners, LP | -74,333 | - | - | 50,000 | Apr 11, 2025 |
Related signals
Other insiders at Keros Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $22k 2,000 shares | +37% | |
| 29Weak | KROSsell Keros Therapeutics, Inc. | Esther Cho SVP, General Counsel | $78k 4,745 shares | -11% | |
| 78Notable | Keros Therapeutics, Inc. | Tomer Kariv director, owner | $85M 4,787,331 shares | -210% | |
| 65Notable | Keros Therapeutics, Inc. | ADAR1 Capital Management, LLC owner | $96M 5,389,264 shares | -123% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.